TORONTO, ON / ACCESSWIRE / February 20, 2020 / Mr. Peng Liangjian, CEO of Hypertension Diagnostics Inc. (OTC PINK:HDII), had a meeting with Mr. Zheng Ding, the chairman of Shanghai CinTel Intelligent Ltd. (CinTel) on February 14, 2020. Mr. Peng introduced Hypertension Diagnostics Inc (HDII) and US Stock Markets to Cintel. Mr. Ding is interested in North American capital markets, and the two discussed the possibilities of bringing the China based company to the U.S. stock markets.
About Shanghai CinTel Intelligent Ltd.
Shanghai CinTel Intelligent Ltd. was established in July 1998, focusing on the deep integration of big data, AI and IoT application technologies. It is a provider of intelligent communication services, big data applications and IoT application solutions. Based on the combination of independent research and development core technology and open source technology, CinTel has created a smart convergence business support platform and a one-stop big data analysis platform.
About Hypertension Diagnostics Inc.
Hypertension Diagnostics, Inc. is a public company currently trading on the OTC Markets (OTC: HDII). HDII was originally corporate in Minnesota .
*Safe Harbor Statement Information in this press release may contain ‘forward-looking statements.’ Statements describing objectives or goals or the Company’s future plans are also forward-looking statements and are subject to risks and uncertainties, including the financial performance of the Company and market valuations of its stock, which could cause actual results to differ materially from those anticipated. Forward-looking statements in this news release are made pursuant to the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to sales, acceptance of Hypertension Diagnostics Inc.’s products, increased levels of competition, changes, dependence on intellectual property rights and other risks detailed from time to time in Hypertension Diagnostic Inc. periodic reports filed with the regulatory authorities.
SOURCE: Hypertension Diagnostics Inc.
View source version on accesswire.com: